On 29 July 2024, UK’s NICE (National Institute for Health and Care Excellence) released a statement that it will not recommend the use of trastuzumab deruxtecan (marketed by Daiichi Sankyo/AstraZeneca as Enhertu®) for treatment of HER2-low breast cancer patients after chemotherapy in the NHS. The decision is based on clinical trial evidence which determined that the drug was a cost-ineffective investment for the NHS in comparison to its proposed benefits.
While Enhertu® will not be available within the NHS for HER2-low patients, in April 2024, it was recommended for listing on Australia’s (PBS) for this population. Enhertu® has previously been approved for HER2-low breast cancer in China (July 2023), Japan (March 2023), Europe (January 2023) and the US (August 2022).